Global Toxoid Vaccine Market

Toxoid Vaccine Market Overview

The global Toxoid Vaccine market size is expected to grow with a CAGR of 6.1% over the forecast period, 2022-2028. The growing incidence of tetanus and diphtheria, rising government initiatives for vaccination programs, and increasing investment in new vaccines’ research & development activities are the primary factors accelerating the growth of the global Toxoid Vaccine market during the forecast period. Furthermore, increasing awareness about the severity of tetanus and the growing availability of several doses of toxoid vaccines for diagnosis and treatment of tetanus and diphtheria among various emerging economies has also boosted the growth of the global Toxoid Vaccine market.

What is Toxoid Vaccine?

Toxoid vaccines use toxins (harmful products) produced by certain bacteria that cause diseases. Toxoid vaccines develop immunity to the parts of the bacteria that cause disease instead of the bacteria itself. Toxoid vaccines are used to treat or protect against Diphtheria and Tetanus. Diphtheria can cause serious complications, like paralysis, pneumonia, and lung failure. It can also be deadly, especially for certain age groups 1 in 10, and people can also die from diphtheria even with treatment. Tetanus is caused by bacteria (Clostridium tetani), leading to muscular spasms across the body. One of the most typical signs of tetanus is painful tightening in the jaw muscles, making it hard to open the mouth, breathe, or swallow.

Growth Driver

Increase in the prevalence of the Diphtheria and Tetanus disease

The rising prevalence of tetanus and diphtheria and the rise in immunization programs, especially in developing economies, are the major factors driving the growth of the global Toxoid Vaccine market during the forecast period. Tetanus is a non-communicable disease contracted through exposure to the bacterium’s spores, Clostridium tetani, and people of all ages can get tetanus, but the disease is particularly common and serious in newborn babies and their mothers. In addition, older children need one booster shot of the vaccine at age 11 or 12 as part of their routine vaccine schedule, and adults need one booster shot of the vaccine every ten years as part of their routine vaccine schedule. The toxoid vaccines protect against Diphtheria, Tetanus, and pertussis by developing immunity against the pathogen causing these diseases. The low cost of the tetanus vaccine, increasing government initiatives for vaccination programs, increasing investments in the development of toxoid vaccines, and technological breakthroughs will further stimulate the growth of the global toxoid vaccines market in the coming years. However, some restraining factors in the global toxoid vaccines market are several side-effects associated with toxoid vaccine, pain at the injection site, and rise in the personalized medicines for the treatment.

Pre-Covid-19 impact on global Toxoid Vaccine market

The significant increase in immunization against infectious diseases that can cause serious illness and disability or be fatal has stimulated the demand for the global toxoid vaccine market in the pre-COVID era. Various government and health organizations are taking various initiatives and organizing various vaccination programs to protect children against more diseases such as diphtheria, tetanus, and pertussis, resulting in the increased demand for toxoid vaccines across the globe.

Covid-19 impact on global Toxoid Vaccine market

The outbreak of the COVID-19 pandemic has significantly impacted the growth of the global Toxoid Vaccine market in 2021. According to WHO, it was estimated that the COVID-19 pandemic and associated disruptions had weakened health systems, with 23 million children being out on vaccination in 2020, 3.7 million more than in 2019 and the highest number since 2009. In 2020, nearly 83% of infants globally (113 million infants) received three doses of the diphtheria-tetanus-pertussis (DTP3) vaccine, shielding them against infectious diseases that can cause serious illness and disability be fatal. This slowdown will likely continue as countries focus on ongoing efforts to control the Covid-19 pandemic and introduce Covid-19 vaccines.

Post Covid-19 impact on global Toxoid Vaccine market

Various government and health organizations are working with countries and partners to improve global vaccination coverage and restore services so that countries can safely provide routine immunization services during the COVID-19 pandemic by adhering to hygiene and physical distancing guidance and providing protective equipment to health workers, which is expected to increase the growth of the global Toxoid Vaccine market in the coming years. Furthermore, new treatment options, government initiatives to implement vaccination programs in developing countries, investments in the development of toxoid vaccines, and technological breakthroughs are anticipated to open new avenues for the growth of the global toxoid vaccine market during the forecast period.

Disease Segmental Analysis

Based on the Disease, the global Toxoid Vaccine market is categorized into Tetanus, Diphtheria, Pertussis, and Others. The Tetanus System segment is expected to hold the highest share in the global Toxoid Vaccine market in the coming years. This growth is attributable to the increasing incidence of tetanus and the rising need for vaccines to protect people from tetanus across the globe. Tetanus is very uncommon but can be a dangerous disease, and the difficulties can be serious and even deadly. People who suffer from tetanus can have trouble breathing and painful muscle spasms that are strong enough to break bones. Tetanus can also cause paralysis. Furthermore, there is no cure for tetanus; getting vaccinated is the best way to prevent tetanus among people of all age groups. Source: World Health Organization/UNICEF

Region Segmental Analysis

The Toxoid Vaccine market is characterized by North America, Europe, Asia Pacific, South America, and Middle East & Africa. The Asia Pacific region is expected to dominate the global Toxoid Vaccine market in 2021 and will continue in 2022-2028. This growth is attributable to the increasing population, rising number of tetanus and diphtheria, and increasing government initiatives towards technological improvements regarding immunization and vaccination, especially in developing countries. Furthermore, Africa and Latin America region is expected to have significant growth in the toxoid vaccine market during the forecast period, owing to the increasing focus of various leading health organizations on various African and Latin America’s Caribbean countries for immunization.

Competitor Analysis

Companies include Bharat Biotech, GlaxoSmithKline plc, Grifols, S.A., Pfizer Inc., Haffkine Bio-Pharmaceutical Corporation Ltd, Integrated Bio Therapeutics, Inc., Abbott, Avalon Pharma Private Limited, Emergent Biosolutions Inc., Merck & Co., Inc., Sanofi, Panacea Biotec, Henry Schein Medical, and Other Prominent Players are the key players in the Toxoid Vaccine market. Key Stakeholders

• Market research and consulting firms
• Industry associations
• Global Toxoid Vaccine manufacturing firm
• Local Governments
• Regulatory bodies
• Suppliers
• Retailers

Scope of the Report

Report Attribute	Details
Market Size Value in 2021	USD Million
Growth Rate	CAGR of 6.1% from 2022 to 2028.
Historical data	2017 – 2020
Base Year	2021
Forecast period	2022 – 2028
Region covered	America, Europe, Asia-Pacific, South America, and Middle East & Africa
Key companies Profiled	Bharat Biotech, GlaxoSmithKline plc, Grifols, S.A., Pfizer Inc., Haffkine Bio-Pharmaceutical Corporation Ltd, Integrated Bio Therapeutics, Inc., Abbott, Avalon Pharma Private Limited, Emergent Biosolutions Inc., Merck & Co., Inc., Sanofi, Panacea Biotec, Henry Schein Medical, and Other Prominent Players.

Market Modelling

By Disease

• Tetanus
• Diphtheria
• Pertussis
• Others

By Application

• Human Vaccines
• Veterinary Vaccines
  • Companion Animals
  • Livestock Animals

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By End-User

• Hospitals
• Independent Clinics
• Specialty Centres
• Others

By Region

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Deodorant and Face Care Product Market

Breast Prosthesis Market

Hydrogen Peroxide Market

Global Fermentation Starter Kit Market

Video-Based Customer Identification Process Market

Global Unmanned Ground Vehicles (UGV) Market

Kaolin Market

Pet Food Extrusion Market

Premium Motorcycle Helmet Market Excel Data

Video-Based Customer Identification Process Market